Impact of ERAS on Postoperative Nausea and Vomiting After Sleeve

Launched by MINIA UNIVERSITY · Aug 9, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at how a special approach called Enhanced Recovery After Surgery (ERAS) can help reduce nausea and vomiting after a type of weight loss surgery known as laparoscopic sleeve gastrectomy (LSG). LSG is performed on patients with severe obesity to help them lose weight and improve their overall health. The trial aims to see if using a combination of different medications can better prevent nausea and vomiting in patients who are at higher risk for these issues after surgery.

To participate in the trial, you need to be between 18 and 60 years old, have a body mass index (BMI) of 40 to 60, and be scheduled for elective sleeve gastrectomy surgery. However, if you have certain health conditions or allergies to specific medications, you may not be eligible. If you join the trial, you can expect to receive care following the ERAS guidelines, which focus on improving recovery after surgery. This study is important because it could lead to better strategies for managing postoperative nausea and vomiting, helping patients feel more comfortable during their recovery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • \* Age: 18-60 years
• • Sex: Both sex
• • ASA Physical Status: II, III.
• • Body mass index: Between 40 and 60 kg/m2.
• • Participants: Patients who are undergoing elective Sleeve Gastrectomy
• Exclusion Criteria:
• • Patients with hypersensitivity or contraindication to haloperidol, dexamethasone, or ondansetron.
• • Serious complications in the perioperative period (such as shock, cardiac arrest, hemorrhage, needing transfusion).
• • Psychiatric disorder.
• • History of migraine.
• • Use of opioid, hormonal, anti-inflammatory, and antiemetic medication 24 h prior to surgery.